Pharming CEO Fabrice Chouraqui Steps Down Immediately; Interim Co-CEOs Named
PHAR is trading near its 52-week low of $9.62 (9.4% above the low).
Summary
Pharming announced CEO Fabrice Chouraqui is stepping down immediately due to strategic misalignment with the board. CCO Leverne Marsh and CFO Kenneth Lynard will serve as interim Co-CEOs while a permanent successor is sought.
Key Events · Executive and Board Changes · PHAR
-
CEO Steps Down Immediately
Fabrice Chouraqui departs as CEO and Executive Director effective September 29, 2026, after the board concluded views on advancing company strategy were not sufficiently aligned.
-
Interim Co-CEOs Appointed
CCO Leverne Marsh will lead patient-focused operations and CFO Kenneth Lynard will lead global corporate functions, effective immediately.
-
Strategic Disagreement Cited
The board explicitly stated the transition followed discussions about execution of strategic priorities for the next phase of the company, with views not sufficiently aligned.
-
Permanent Successor Search Underway
The board has started a formal search for a permanent CEO; no timeline or candidate was disclosed.
Analysis · PHAR · Life Sciences
Pharming's CEO is out effective immediately after the board concluded views on strategy were 'not sufficiently aligned.' That is a sharp, unexpected leadership rupture at a company that just cut full-year revenue guidance by $30M in July and is mid-launch on Joenja. The board has installed two interim Co-CEOs — the Chief Commercial Officer and the CFO — while it searches for a permanent successor. The immediate nature of the departure, the explicit strategic disagreement, and the absence of a named successor all point to governance instability at a critical commercial moment.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 36.4% of the 960 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAR was trading at $10.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $740.3M. The 52-week trading range was $9.62 to $21.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.